monoclonal antibody
Recently Published Documents





Food Control ◽  
2022 ◽  
Vol 134 ◽  
pp. 108751
Jiao Li ◽  
Yuan Ding ◽  
He Chen ◽  
Wanlin Sun ◽  
Yue Huang ◽  

2022 ◽  
Vol 192 ◽  
pp. 106046
Zenglei Hu ◽  
Ya Huang ◽  
Jiangyan Zhao ◽  
Jiao Hu ◽  
Shunlin Hu ◽  

2022 ◽  
Vol 72 ◽  
pp. 248-259
Beatriz Trastoy ◽  
Jonathan J. Du ◽  
Mikel García-Alija ◽  
Chao Li ◽  
Erik H. Klontz ◽  

Anastasia S. Lambrou ◽  
John T. Redd ◽  
Miles A. Stewart ◽  
Kaitlin Rainwater-Lovett ◽  
Jonathan K. Thornhill ◽  

Abstract Monoclonal antibody therapeutics to treat COVID-19 have been authorized by the U.S. Food and Drug Administration under Emergency Use Authorization (EUA). Many barriers exist when deploying a novel therapeutic during an ongoing pandemic, and it is critical to assess the needs of incorporating monoclonal antibody infusions into pandemic response activities. We examined the monoclonal antibody infusion site process during the COVID-19 pandemic and conducted a descriptive analysis using data from three sites at medical centers in the U.S. supported by the National Disaster Medical System. Monoclonal antibody implementation success factors included engagement with local medical providers, therapy batch preparation, placing the infusion center in proximity to emergency services, and creating procedures resilient to EUA changes. Infusion process challenges included confirming patient SARS-CoV-2 positivity, strained staff, scheduling, and pharmacy coordination. Infusion sites are effective when integrated into pre-existing pandemic response ecosystems and can be implemented with limited staff and physical resources.

Monique Hartley-Brown ◽  
Paul Richardson

Targeted immunotherapy has arisen over the past decade to the forefront of cancer care. Notably, targeted therapies such as antibody-drug conjugates (ADCs) are becoming more recognized for a novel approach in cancer treatment. The mechanism of action of ADCs incorporates a monoclonal antibody portion directed against the tumor cell antigen and attached to the tumoricidal portion via chemical linkage. The binding of the monoclonal antibody portion allows for tumor cell internalization of the ADC and precise release of the toxic payload within the cancer cell. Multiple myeloma (MM) is an incurable cancer for which belantamab mafodotin was the first-in-class ADC to achieve United States Food and Drug Administration (FDA) approval for treatment of this disease. Clinical trials are currently evaluating other ADCs in the treatment of MM. In this review, a look at the current ADCs being tested in MM clinical trials with a focus on those that are more promising and a potential next-in-line for FDA approval for treatment of MM is discussed.

2022 ◽  
Vol Publish Ahead of Print ◽  
Bright P. Thilagar ◽  
Aditya K. Ghosh ◽  
Jerome Nguyen ◽  
Regan N. Theiler ◽  
Myra J. Wick ◽  

2022 ◽  
pp. 107815522110737
Mustafa Korkmaz ◽  
Engin Hendem ◽  
Melek Karakurt Eryılmaz ◽  
Aykut Demirkıran ◽  
Mustafa Karaağaç ◽  

Introduction Cetuximab, an anti-EGFR monoclonal antibody, often cause skin toxicity, most commonly acneiform rash. We present a rare case of glomerulonephritis associated with cetuximab therapy. Case Report A 58-year-old male patient recently completed cetuximab-based chemotherapy for metastatic colorectal adenocarcinoma. He presented with acute renal failure, anasarca edema and nephrotic proteinuria. The amount of protein in the 24-h urine test was over 15.6 grams. Management & Outcome The patient showed a dramatic improvement in renal function shortly after terminated of cetuximab therapy without immunosuppressive therapy. Discussion Therefore, drugs targeting epidermal growth factor receptor (EGFR) monoclonal antibody were thought to trigger nephrotic syndrome by causing glomerular damage. As a result, physicians using EGFR monoclonal inhibitors should be very careful about renal functions and proteinuria in patients.

Sign in / Sign up

Export Citation Format

Share Document